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Abstract: Three-dimensional printing, also known as additive manufacturing, is a fabrication process
whereby a 3D object is created layer-by-layer by depositing a feedstock material such as thermoplastic
polymer. The 3D printing technology has been widely used for rapid prototyping and its interest
as a fabrication method has grown significantly across many disciplines. The most common 3D
printing technology is called the Fused Deposition Modelling (FDM) which utilises thermoplastic
filaments as a starting material, then extrudes the material in sequential layers above its melting
temperature to create a 3D object. These filaments can be fabricated using the Hot-Melt Extrusion
(HME) technology. The advantage of using HME to manufacture polymer filaments for FDM printing
is that a homogenous solid dispersion of two or more pharmaceutical excipients i.e., polymers can
be made and a thermostable drug can even be introduced in the filament composition, which is
otherwise impractical with any other techniques. By introducing HME techniques for 3D printing
filament development can improve the bioavailability and solubility of drugs as well as sustain
the drug release for a prolonged period of time. The latter is of particular interest when medical
implants are considered via 3D printing. In recent years, there has been increasing interest in
implementing a continuous manufacturing method on pharmaceutical products development and
manufacture, in order to ensure high quality and efficacy with less batch-to-batch variations of the
pharmaceutical products. The HME and FDM technology can be combined into one integrated
continuous processing platform. This article reviews the working principle of Hot Melt Extrusion
and Fused Deposition Modelling, and how these two technologies can be combined for the use of
advanced pharmaceutical applications.
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1. Introduction
The 3D printing technology was first introduced by Charles Hull in the early 1980s [1]. It is a
manufacturing process that creates a three-dimensional object layer-by-layer from a 3D digital model
that can be generated from computer-aided design (CAD) software. Although the technology was
developed in the 1980s, 3D printers were not widely available commercially until the early 2010s [2].
During the early stages, 3D printing was primarily used for making prototypes of products due to
its cost-effectiveness and short production time. It was mainly used in various disciplines for the
design and testing phase in the development of a new product. Three-dimensional printing has major
advantages over traditional rapid prototyping processes, as the materials used in 3D printers are less
expensive and it is able to provide a faster mode of iteration [2]. The rapid growth and improvement
in the 3D printing technology have made it not just a rapid prototyping technique, but also a preferred
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production method in major industries [3–5]. Therefore, 3D printing is considered a very cost-effective
manufacturing process, especially in producing objects with high complexity. It is now a preferred
method to produce custom-designed objects, which could be very expensive and time-consuming
using conventional manufacturing techniques such as injection moulding, machining and casting [5–8].
Nowadays, 3D printing technology is being used across various industries including architecture [9],
construction [10], automotive [11], food [12], fashion industry [13], medical sector [1] and many others.
The 3D printing technology has gained much popularity in the healthcare and medical field not just
for its cost-effectiveness but also for the manufacturing flexibility. It is very useful in creating devices
or medicine that are tailor-made for specific patients. The healthcare market in using 3D printing is
expected to show significant growth due to increasing demand for custom-tailored and patient-specific
medical products. The ability of 3D printing to produce rapidly only with a CAD model, allows for
on demand-fabrication, creating the possibility for medical devices to be produced in-house. Custom
made prostheses, hearing aids and some implants have been successfully made using the 3D printing
technology. It can also fabricate the 3D constructs from a patient’s own medical images, such as
computed axial tomography (CAT) and magnetic resonance imaging (MRI) [14]. These parts could be
very useful for surgeons to practice on before performing a surgery on the real patient, and can also be
used as a guidance and explanation of the operation procedure to the patient [15].
The Hot-Melt Extrusion (HME) technology was established in the early 1930s and was originally
used for the manufacturing of plastics and rubber products [16]. This technology can be used to
produce the filaments that are required to be used in Fused Deposition Modelling (FDM) 3D printers.
In recent years, this technology has gained much interest in the pharmaceutical industry, especially
for the production of oral dosage forms and drug delivery systems. Apart from that, drug loaded
filaments which are suitable for 3D printing has also been produced. In the HME process, active
pharmaceutical ingredients (APIs) are blended with a thermoplastic polymer and then extruded as
filaments that are used in 3D printing. This article will provide a review on the mechanism of HME,
FDM 3D printing and integrating HME with FDM 3D printing as a continuous process to produce
pharmaceutical dosage forms.
2. Mechanism of Hot-Melt Extrusion (HME)
HME is a continuous process where heat and pressure are applied to melt or soften materials
through an orifice to produce new products of uniform shape and density. The extrusion process
can change the physical properties of a substance when it is being forced through an orifice or die
on the hot-melt extruder under controlled conditions [17]. The main component of HME is the
extruder. Some of the basic elements that are assembled to make an extruder include a motor, an
extrusion barrel, rotating screws in the barrel and a die or orifice that is connected at the end of
the extruder [17]. The extrusion barrel containing the rotating screws is often made up of several
sections that are bolted together. The extruder contains heaters that provide heat for the melting or
softening of the materials. The screws in the extruder can provide shear stress and intense mixing
of the materials. The friction created by the screws in the barrel and the heat provided cause the
polymeric material to melt. The screw then conveys the melted material down the barrel. The extruder
is controlled through a central electrical control, which is connected directly to the extrusion unit. Some
of the processing parameters that can be controlled are screw speed in revolutions per minute (RPM),
feed rate, temperature along the barrel and the die, and the vacuum level for devolatilization [17].
A schematic diagram of a typical extruder is illustrated in Figure 1.
Pharmaceutics 2018, 10, 203 3 of 23
Pharmaceutics 2018, 10, x FOR PEER REVIEW  3 of 23 
 
 
Figure 1. A schematic diagram of a typical hot melt extruder (Reproduced with permission from 
reference [17], Springer, 2015). 
In general, there are two types of hot-melt extruders: the single-screw extruder and twin-screw 
extruder (Figure 2). Some of the advantages and disadvantages of the single-screw extruder and the 
twin-screw extruder is compared in Table 1. The primary purpose of a single-screw extruder is to 
melt polymers and extrude them into a continuous shape. In the single screw extruder, there is only 
one screw in the extruder, which is used for feeding, melting, devolatilising and pumping [18]. 
Materials are fed into the extruder from the feeder/hopper and then transported down the barrel 
using the screw. Most single screw extruders are flood fed, which means the feeder sits over the feed 
throat and the speed of the screw determines the output rate. Occasionally, the single screw extruder 
can also be starve fed, where a feed system sets the mass flow rate and the output rate is independent 
of the screw speed [18]. When the extruder is starve fed, it is fed at a rate less than the forwarding 
efficiency of the screws [19]. When the screw rotates in the extruder barrel, frictional forces are created 
between the rotating screw and the surface of the barrel, forming a flow channel that is responsible 
for transporting the material fed down the barrel to the proximal end of the screw [17]. Increasing the 
screw speed can increase the frictional forces created, resulting in higher heat energy created. The 
shearing caused by the rotating screw and the heat energy produced from the heaters will melt the 
material, which will then result in a melt pool of the material. The molten material will then be 
pumped through a die, which will give a fixed shape that forms the extrudate [18]. However, high 
pressure may be created during the melting process in a single-screw extruder. The high pressure 
will compress the dispersed particulates in the molten material, which could cause agglomeration 
and poor mixing due to insufficient shear deformation. 
 
Figure 2. Cross-section of a single and twin-screw extruder (Reproduced with permission from 
reference [17], Springer, 2015). 
Figure 1. A schematic diagram of a typic l t lt t er (Reproduced with permission from
reference [17], Springer, 2015).
In gen ral, ther are two types of hot- elt t : the single-screw extruder and twin-screw
extruder (Figure 2). Some of the advantages tages of the single-screw extruder and the
twin-screw extruder is compared in Table 1. The primary purpose of a single-screw extruder is to melt
polymers and extrud them into a continuous shape. In the single screw extruder, there is only one
screw in the extruder, which is used for feeding, melting, devolatilising and pumping [18]. Materials
are fed into the extruder from the feeder/hopper and then transported down the barrel using the
screw. Most single screw extruders are flood fed, which means the feeder sits over the feed throat and
the speed of the screw determines the output rate. Occasionally, the single screw extruder can also be
starve fed, where a feed system sets the mass flow rate and the output rate is independent of the screw
speed [18]. When the extruder is starve fed, it is fed at a rate less than the forwarding efficiency of the
screws [19]. When the screw rotates in the extruder barrel, frictional forces are created between the
rotating screw and the surface of the barrel, forming a flow channel that is responsible for transporting
the material fed down the barrel to the proximal end of the screw [17]. Increasing the screw speed
can increase the frictional forces created, resulting in higher heat energy created. The shearing caused
by the rotating screw and the heat energy produced from the heaters will melt the material, which
will then result in a melt pool of the material. The molten material will then be pumped through
a die, which will give a fixed shape that forms the extrudate [18]. However, high pressure may be
created during the melting process in a single-screw extruder. The high pressure will co press the
dispersed particulates in the molt material, which could cause agglomeration and poor mixing due
to insufficient shear deformation.
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Table 1. Advantages and disadvantages of single-screw and twin-screw extruder.
Type of Extrusion Advantages Disadvantages
Single-screw extrusion
• Mechanical simplicity
• Low maintenance
• Low cost
• High tendency
of overheating
• Not suitable for
heat-sensitive materials
• Poor mixing
Twin-screw extrusion
• Easier material feeding
• Higher kneading and
dispersing capacity
• Lower tendency to overheat
• Higher process productivity
and flexibility
• Better control of process parameters
• Enhanced mixing
• High input energy
• Not suitable for
shear-sensitive materials
On the other hand, the twin-screw extruder uses two screws arranged side-by-side in the barrel.
The twin-screw extruder is used mainly for the purpose of mixing two or more materials together
to form a blend. The additional materials that could be melted and mixed with polymers are, for
example, pigments (e.g., iron/chromium oxide [20]), fillers (e.g., lactose, starch [21]), APIs (e.g.,
acetaminophen [22]) and plasticisers (e.g., polyethylene glycols, Triacetin [21]) [23]. Most of the
time, a twin-screw extruder will be starve fed with the raw materials. This means that the output
rate of the extrudates will depend on the feeder and independent of the screw speed [24]. In a
twin-screw extruder, the screws can either be co-rotating (screws rotate in the same direction) or
counter-rotating (screws rotate in the opposite direction) (Figure 3). The counter-rotating screws
can produce very high shear forces as the materials are squeezed into the gaps between the two
screws [18]. These two types of twin-screw extrusions can further be classified into fully intermeshing
or non-intermeshing. The fully intermeshing twin-screw extruder has a special self-cleaning feature,
which can help reduce the non-motion during the extrusion process and also prevents localised
overheating of the raw materials when inside the extruder. This is because the raw materials do not
rotate along the screw in the intermeshing screws configuration. The flight of one of the screws will
be able to clean the root of the adjacent screw, removing all the materials away from the extruder
assembly during the extrusion process. This can also reduce any product waste that could happen at
the end of a production batch. The non-intermeshing extruder has a weaker screw interaction and
lower self-cleaning capability, making it not as popular as the intermeshing screws for material mixing
applications. The non-intermeshing screws are often used to process highly viscous materials and can
be used to remove large amounts of volatile substances. The non-intermeshing screws are positioned
separately from each other, resulting in a lower torque generation, which is suitable for processing
highly viscous materials [17].
For twin-screw extruders, the shearing of the materials occurs between the rotating screws and
between the screws and the wall of the barrel. The torque and shear created by the rotating screws
produce heat energy that is used to melt the materials. When the melted material is being squeezed
between the gaps of the rotating screws, it is being continuously stretched as a rubber band, causing
viscous heating dissipation to occur [24]. The heat generation in a twin-screw extruder is independent
of the screw speed. The configurations of the twin screw can be adjusted depending on the desired
level of shear and mixing. This means that there is a better control of the melting of the materials in
a twin-screw extruder. Hence, there is a lower tendency of overheating, which is particularly useful
when processing heat sensitive materials [17].
The main feature of a twin-screw extruder is the enhanced and homogenous mixing of materials
during extrusion. During twin-screw extrusion, two types of mixing can occur (a) distributive mixing
and (b) dispersive mixing. Distributing mixing involves melt division and recombination. This means
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that the materials can be evenly blended with minimal degradation. Apart from that, the size of
the materials is reduced in distributive mixing. Distributive mixing allows for the use of heat and
shear sensitive materials such as APIs. Dispersive mixing involves shear and elongational mixing [24].
It induces solubilisation of one component to another component. Dispersive mixing breaks down
the droplet or solid materials to fine particles using high energy. The enhanced mixing feature in the
twin-screw extruder contributes to the viscous heat dissipation. These make the twin-screw extruder
more efficient in heating the materials, and hence, it can readily process thermoplastic polymers (e.g.,
hydroxypropyl cellulose) [24]. Some other advantages of a twin-screw extruder over a single-screw
extruder are easier material feeding, high kneading and dispersing capabilities, lower tendency of
overheating and shorter transit time [17]. As twin-screw extrusion provides uniform and homogenous
mixing, the twin-screw extrusion process can be easily scaled up and optimised. The possibility
of scaling up the extrusion process makes it a more efficient process for large volume production.
Therefore, the majority of the food and plastics industries have been using twin-screw extrusion for their
production [25–27]. Apart from that, twin-screw extrusion has also been adopted as a manufacturing
process in the pharmaceutical field [28]. However, there might be an issue for pharmaceutical industry
when it comes to the development of a formulation containing some expensive drug/material.
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The screw in the hot-melt extrusion process is very important in determining the mixing and
the extrusion process. Figure 4 shows the parameters of a typical screw used in a hot-melt extruder.
The dimensions of the screws are normally defined in length-to-diameter (L/D) ratio. Most screws
are coated with stainless steel which could reduce friction and avoid chemical reactions with the raw
materials. The screw is typically divided into three sections along the length of the barrel: the feed
section, melting/compression and metering (Figure 5). At the feed section, the screw transfers the
materials from the hopper to the barrel. The screw in the feed section has flights that are deeper or of a
greater pitch, and the channel depth is also wider. This allows for the raw material to fall easily into the
screw for conveyance along the barrel and to facilitate mass flow. The pitch and helix angles determine
the output of the extruder at a constant screw speed. The solid raw materials are then conveyed to the
compression zone for mixing, compressing, melting and plasticising. The channel depth decreases the
compression zone in order to increase the pressure in the barrel which could remove any entrapped air.
The polymers will then soften and melt in the compression zone. As the material enters the metering
zone, the material should be in molten state. The metering section is to reduce the pulsating flow and
to ensure a uniform delivery rate through the die [17,18].
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The last section of the extruder is the die or orifice. The function of the die is to shape the
molten material when it is exiting the extruder. It is designed to achieve the required shape and
dimensions of the extrudate. The cross-section of the extrudate will increase upon leaving the die
and this phenomenon is known as “die swell” [18]. This phenomenon depends on the viscoelastic
properties of the polymers [30]. In general, there can be four different shapes for products made by
extrusion dies including the extrudate strands, films, sheets and granules [17].
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3. Hot-Melt Extrusion in Pharmaceutical Applications
Hot-melt extrusion is a continuous manufa turi g process that includes several operations such
as feeding, heating, mixing and shaping into one continuous process. There has been growing
interest in implementing continuous manufacturing processes on pharmaceutical product in the
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pharmaceutical industry [24]. Therefore, the HME technology has received much attention from the
medical and pharmaceutical industry for the production of pharmaceutical dosage forms and medical
implants [31]. The number of HME patents issued for pharmaceutical applications has increased
significantly since the 1980s (Figure 6) [32]. This is because the HME process is able to meet the
regulatory requirements in the manufacturing process of dosage forms and also have large flexibility,
particularly for the increasing demand for personalised medicines. Regulatory bodies such as the U.S.
Food and Drug Administration’s (FDA) encourages manufacturing processes that involves process
analytical technology (PAT) in order to enhance product and process understanding. The initiative
of PAT is to closely monitor some key parameters during the manufacturing process which could
help to optimise design, analysis and control within the manufacturing process [19,30]. This is can be
demonstrated and fulfilled in the HME process.
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Figure 6. Number of Hot-Melt Extrusion patents issued for pharmaceutical applications between year
1983 to 2006 (the data for chart is extracted from reference [32], Taylor & Francis, 2008).
During the hot-melt extrusion process of pharmaceutical dosage forms, APIs, thermoplastic
polymeric carrier and processing aids such as plasticisers and antioxidants, are heated and mixed
in the extruder and then being forced through a die into shapes including granules, cylinder or
films [33]. In recent years, much work has proven that HME has the ability to improve the solubility
and bioavailability of poorly soluble drugs [34]. For instance, the bioavailabilty of poorly soluble
APIs (e.g., Ritonavir, Troglitazone, Anacetrapib, Suvorexant) can be improved when being used a
type of formulation called the solid dispersion which can be prepared using HME [16,34]. A solid
dispersion is a system where one or more APIs are molecularly distributed into a hydrophilic inert
carrier matrix. The matrix can either be crystalline or amorphous, and the APIs will be dispersed
molecularly in crystalline particles or amorphous particles [17,35]. In the early 1990s and 2000s, the
Rezulin® and Kaletra® tablets have been successfully produced using the HME process, which have
shown improved bioavailability. These two tablets were produced using twin-screw extrusion as it can
provide homogeneous and consistent mixing of multiple ingredients [24]. Since then, the HME process,
and in particular, the twin-screw extrusion, has gained much popularity in the pharmaceutical industry.
The powerful processing technology of HME has also attracted much attention in developing
different types of drug delivery systems, as it has opened up the opportunity to use some of the
molecules that were previously seemed not suitable to be made into pharmaceutical dosage forms [32].
Its ability and efficiency in producing solid dispersions has also made it possible for the development
of sustained, modified and targeted drug delivery systems. The different drug release systems can be
achieved by controlling the formulations and the processing parameters when using HME [17].
As seen is some early studies, HME has been used to develop sustained release matrix mini-tablets
manufactured from ethyl cellulose, HPMC and ibuprofen [36,37]. Vegetable calcium stearate (CaSt)
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was also seen reported in the development of sustained release pellets using as a thermoplastic
excipients [38]. A microbicide intravaginal ring (IVRs) IVR was also prepared and developed
from polyether urethane (PU) elastomers for the sustained delivery of UC781 [39]. There has been
also a study where HME was used to produce sustained-release solid lipid matrices of diclofenac
sodium (Df-Na), and the extruded products were being compressed into tablets [40]. A lipophilic
excipient, Glyceryl dibehenate (Compritol 888 ATO (C-888)) was used for the development of Df-NA
sustained-release lipid matices. The purpose of the study is to investigate the effects of some parameters
(e.g., extrusion temperatures, formulation composition, drug-lipid ratio) on the drug release behavior.
It is found that Df-Na can either be in the crystalline or amorphous state depending on the processing
conditions. The dissolution rate is affected by the drug–lipid ratio and the extrusion temperatures.
There was an excellent distribution of Df-Na on the surface of the compressed tablets. The study has
proven that Df-Na sustained-release tablets can be effectively produced by processing solid lipids
using HME [40].
Bruce et al. have successfully developed tablets to target deliver 5-aminosalicylic acid (5-ASA) to
the colon [41]. The tablets, prepared using the HME technique, are able to homogeneously disperse
the crystalline 5-ASA throughout the polymeric matrix. The polymeric carriers used are Methacrylic
Acid—Methyl Methacrylate Copolymer (1:2) and Eudragit® S 100. Two types of plasticisers (Triethyl
Citrate (TEC) and citric acid) were used in the study. TEC was able to reduce the glass transition
temperature of the polymer, thus lowering the processing temperature. It can also affect the drug
release rates of the tablets due to the leaching of TEC during the dissolution testing. The citric acid
causes a slower drug release rate as it causes a decrease of the pH in the microenvironment of the
tablet, which suppresses the polymer ionisation. The drug release profiles of the tablets were found to
fit both the diffusion and surface erosion model [41].
Apart from developing drug delivery systems with different release patterns, HME can also be
used to create drugs that could mask the bitterness of APIs. There are still a significant number of drugs
on the market that have very poor organoleptic properties, which makes it unpalatable, especially for
paediatric and geriatric medications. In order to improve the palatability of the drugs, taste masking
has been an important consideration for the development of a formulation [42]. There are works
that have shown that pharmaceutical dosage forms produced using the HME process can mask the
bitter taste of APIs. This can be done by mixing the taste-masking polymer with the APIs during the
production of a solid dispersion. The solid dispersion can prevent the interaction between the drug
molecules and the taste bud by preventing the release of bitter drugs in the saliva [17]. Eudragit E-PO
has been widely used as a taste-masking excipient in formulations, as it is insoluble below pH 5, thus
preventing the release of the drug in the mouth [42].
When an extruder is used for pharmaceutical applications, it is required to meet some regulatory
requirements. Therefore, some parts are different from the extruder which is used for manufacturing
plastics. The metallurgy of the contact parts must not be reactive, additive or absorptive with the
product, and these parts are made of medical grade steel. The oils and lubricants used are also fully
FDA-conformant. The equipment needs to be configured for the cleaning and validation requirements
associated with a pharmaceutical environment [18]. A comprehensive documentation of the process
is required for monitoring and controlling the parameters such as feed rate, temperature, screw
speed, pressure, melt viscosity, drive amperage and torque. The temperature in the barrel needs to
be optimised so that the viscosity of the melted material is low enough to be transported down the
barrel, but still sufficient for proper mixing. Apart from that, the temperature should also be kept low
enough to avoid thermal degradation of the materials. There are also good manufacturing practices
(cGMP) guidelines for the cleaning of HME used for pharmaceutical applications. The extruder for
pharmaceutical purposes have been redesigned to enhance the ease of disassemble and limit the dead
spots, allowing for efficient cleaning and maintenance. The equipment must be cleaned at appropriate
intervals and written procedures are required that must be specific and detailed. Cleaned equipment
must be protected from contamination while in storage and inspected before being used. Records and
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equipment logs of all cleaning and inspection must be kept. The time between the end of processing
and cleaning steps must be recorded [19]. During cleaning, the extruder assembly is disassembled and
any materials present on the screw, barrel and die need to be removed. The surfaces then need to be
swabbed and analysed to satisfy cleaning validation requirements [33].
There are many advantages in using HME for pharmaceutical applications, which makes the
technology more popular as a manufacturing method for pharmaceutical products. HME can be
modified to include appropriate PAT tools, making it a continuous manufacturing process, which is a
fabrication method that is highly encouraged by FDA as it meets the goal of PAT scheme to improve
the efficiency and effectiveness of manufacturing process design, control and quality assurance [43].
One other reason for HME to be a preferred method is that the process does not require any use of solvent
when producing solid dispersions. Traditional formulation methods, such as roll spinning and spray
drying, require the use of organic solvents. These organic solvents can cause environmental issues when
being disposed. As HME is a solvent-free process, this makes it an environmentally friendly process,
making it a preferred process over conventional methods [42]. Some other advantages of using HME in
pharmaceutical applications include shorter production time, higher process efficiency, and increases
drug delivery efficiency in patients [33]. The biggest advantage of using HME in pharmaceutical is the
prospect of being able to create new and novel formulations through this technique.
However, there are a few drawbacks in the HME process [43]. HME requires high energy input,
which is required for the shear forces and the elevated temperature in the barrel of the extruder.
The high temperature may also cause thermal degradation of the APIs and the high shear forces may
also cause mechanical degradation to the polymers. However, there has been ongoing research work
to overcome these issues, and they can be solved by proper formulation and equipment design, as
well as different engineering approaches [32].
4. Mechanism of Fused Deposition Modelling (FDM)
FDM is considered the most low cost and easily accessible 3D printing technology. FDM based
3D printers are so common that they are even found in homes for personal use, such as normal inkjet
printers. FDM is one of the 3D printing techniques that is available in open source, which makes
this technology the most affordable, as compared to others such as selective laser sintering (SLS),
powder-based 3D printing, and stereolithography (SLA). This is because the open source 3D printing is
shared freely with the public and can be easily built by anyone, making it possible for anyone to have
an FDM 3D printer as a common household object. RepRap is a 3D printing community that started the
open source 3D printer revolution [44]. A survey within the 3D printing community that was done in
2012 shows that RepRap is the most commonly used 3D printer manufacturer [45] (Figure 7). In FDM
3D printers, thermoplastic materials are typically used as the starting material. These thermoplastics
materials that are fed into an FDM printer are usually in the form of a filament. The thermoplastic
filaments are melted or softened, and then extruded from a printer head that is able to move in the
x- and y-direction. The object is formed by many layers of melted thermoplastic. Each layer fuses
and bonds to the layers below [46]. The layers of melted thermoplastic solidify almost immediately
after being extruded from the print head. As one layer cools down and solidifies, another layer of the
melted filament will be deposited on top of it until the printing of the object is finished (Figure 8).
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Acrylonitrile Butadiene Styrene (ABS) and Polylactic Acid (PLA) are the two most common
thermoplastics used in FDM machines [48]. High performance thermoplastics such as Polyether Ether
Ketone (PEEK) and Polyether Imide (PEI) are some of the newer thermoplastics that are currently
used in FDM printers [49]. These materials usually have very high melting temperature and excellent
mechanical properties. They have been considered to be a cost-effective alternative to metal in some
applications, as they are strong and also light [50]. PEI is a durable thermoplastic that exhibits physical
properties such as high heat, solvent and flame resistance, high dielectric strength, thermal conductivity
and overall strength. It has a lower impact strength and working temperature than PEEK [51]. Some
of the PEI materials that are compatible with 3D printing have been used to produce plastic parts for
aircraft [51]. Table 2 shows the comparison of different types of thermoplastics that are currently being
used in FDM 3D printing. There are many challenges in using high-performance thermoplastics for
FDM 3D printing due to their chemical and physical properties. As these materials possess very high
melting temperature, the printing environment needs to be in a high temperature as well. This means
that not just the extruder needs to be kept at the melting point of the material, but that the printing
chamber needs to be kept at an evenly distributed high temperature as well during the printing process.
This is because any cool areas will cause the material to shrink unevenly, resulting in warping or even
a lack of bonding in between the layers of the materials [51]. One of the 3D printers that has been
successfully developed by a 3D printing company called INTAMSYS is the FUNMAT HT (Shanghai,
China) is capable of printing various 3D printing materials including ABS, PLA, PEI, etc. [52].
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Table 2. Printing temperature, properties and applications of different thermoplastic materials used in
FDM 3D printing.
Thermoplastic
Materials
Acrylonitrile
Butadiene Styrene
(ABS)
Polylactic Acid
(PLA)
Polyether Ether Ketone
(PEEK) Polyether Imide (PEI)
Printing
temperature (◦C) 220–250 190–220 350–400 355–390
Properties
High strength,
flexibility and
durability
Biodegradable,
biocompatible,
brittle
High mechanical
strength, toughness,
flexibility, chemical and
radiation resistance,
self-extinguishing
properties
High specific strength
(strength-to-weight
ratio), flame resistance,
chemical resistance
Applications
Pipe systems,
automotive, toys,
electronic casing
Biomedical, drug
delivery systems,
food packaging
Electronics, aerospace,
automotive, mechanical
and medical parts
Medical, chemical
instruments, aerospace,
automotive, electronics
Some post-processing might be needed for a 3D printed object using the FDM method as the
surface finish of the object is often quite rough due to the layering of the melted thermoplastics.
Acetone is often used to smoothen ABS so that it has a glossy finish. The 3D printed objects can also
be machined or easily sanded after printing to smooth the surface [49]. It has been proven that some
FDM 3D printed objects have similar mechanical properties as the objects that are manufactured using
traditional injection moulding and machining when the same materials are being used. Therefore, FDM
3D printing can provide a cost-effective alternative for producing these parts. Some high-performance
thermoplastics can also provide strength that is similar to metal parts. The advantage of using 3D
printer thermoplastics over metal is that the thermoplastics products are much lighter than the metals.
Some FDM printers have enhanced features such as having multiple printheads which allow for the
printing of several different materials within an object.
In recent years, 3D printing has been able to attract attention for use in medical and pharmaceutical
applications. It has been adopted by the medical and pharmaceutical industry as a manufacturing
method due to its customisability and the ability to create complex shapes with precision. It has
successfully been used to produce oral dosage forms [53]. The trend of using 3D printing to produce
medicines only started after the approval of the first 3D printed drug by the U.S. Food and Drug
Administration (FDA) in 2015. The first 3D printed drug is called Spritam® (levetiracetam). However,
this medicine is manufactured using the Zipdose technology based on a powder bed-liquid 3D printing
technology [54]. In a powder based 3D printer, a binder solution is required to bind the loose powder
together. The binder solution is sprayed onto the successive layers of powder that is being deposited
onto the print bed [47]. The traditional methods for producing medicines have very limited process
capability and manufacturing flexibility when compared to 3D printing. By using 3D printing, there is
much flexibility in designing the tablets. For instance, tablets can be designed to have interesting and
complex shapes which can be useful for the fabrication of paediatric medicines or modified-release
systems [54,55]. Furthermore, tablets can be designed to contain several drugs that can have different
drug release rates. The research work done by Sadia et al. has been able to produce a novel design of
a tablet that could accelerate drug release of 3D printed tablets. The 3D printed tablets are made of
polymethacrylate and are designed to have built-in channels within the tablet that could increase the
surface area/volume ratio of the tablet and also allow media perforation through the structure [55].
The study carried out by Goyanes et al. has also proven that the FDM 3D printing technology is feasible
of fabricating personalised tablets containing drug doses tailored to individual patients or tablets with
specific drug-release profiles [56]. Apart from that, some research work has been carried out on the
possibility of housing multiple medications within a dosage form. This multi-active solid dosage
form is called ‘polypill’. The ‘polypill’ can also be designed with having different release profiles [57].
One way to achieve this is by changing the exposed surface area or the geometry of the dosage form
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and by using more than one kind of carrier with different release characteristics. The external shape
and volume/mass ratio of a 3D printed tablet can affect the release profile and pattern. The percentage
of infill that can be set during the 3D printing process is one of the parameters that can also affect the
drug release patterns [55,58]. Thus, 3D printing has opened up the possibility of combining multiple
medications in a personalised tablet. This is particularly useful for patients that are currently taking
multiple medications through many separate tablets. Besides that, there is also a flexibility to tailor
a specific drug combination or drug release profile according to the patient’s needs. Therefore, 3D
printing is able to fabricate these personalised medicines in a very timely and cost-effective manner.
5. Coupling HME with FDM 3D Printing
The thermoplastic materials being used in FDM 3D printers need to be in the form of a
filament. However, most filaments currently available in the market are not suitable to be used
for pharmaceutical applications. This issue has been a major obstacle for FDM 3D printing being
used as a main manufacturing method for pharmaceutical products. Apart from that, most traditional
polymer excipients that have been used in pharmaceutics do not have the appropriate thermal and
mechanical properties that can be used to made into filaments that are needed for FDM 3D printing [59].
Some of the most commonly pharmaceutical grade polymers that can be made into filaments are
Polyvinylpyrrolidone (PVP), Polyvinyl alcohol (PVA), and PLA [60]. These are suitable to be made
into filaments due to excellent mechanical and thermal properties, and have been used to mix with
drugs to produce filaments that can be used in a FDM 3D printer to produce oral dosage forms [61,62].
Filaments that are being used in FDM 3D printers need to be of good quality in order to produce a
good quality 3D printed product. During the feeding of the filament into the print head of an FDM
3D printer, the filament will experience tensile and compressive forces caused by the extruding gear,
as well as a large amount of heat for melting. The filaments will need to be able to withstand the
mechanical and thermal stresses in the FDM print head in order to achieve a good printing quality [49].
Good quality thermoplastic filaments can be effectively produced using the HME method. With
twin-screw extrusion in the HME technology, almost any kind of polymer can be mixed during the
HME process in order to produce polymeric filaments for the desired applications. Therefore, there
has been increasing research interest in the development of different types of filaments from different
materials for specific applications using the HME technology. For instance, pure Eudragit has not been
a suitable material to be made into FDM printable filaments due to its brittleness. Sadia et al. have
been able to develop Eudragit-based filaments by mixing it with a plasticiser (triethyl acetate) and
a filler (tricalcium phosphate) using the HME technique [63]. The mechanical properties such as the
flexibility of the Eudragit filament have been further improved and the filaments are suitable to be
used in FDM 3D printers for the fabrication of tablets. The 3D printed tablets also possess excellent
mechanical strength [63]. Due to the robustness of HME in producing novel polymeric filaments for
the use in FDM printers, much research has been carried out to explore the possibility of bridging
HME and FDM 3D printing to increase the range of polymers that can be used with FDM machines.
This approach is seen to be a very efficient and effective way of producing desired materials for FDM
printers. It will also further improve the usability of FDM printers across many industries.
The HME technology and 3D printing technology has shown many advantages when being
used in pharmaceutical applications. These two technologies can streamline the complex processes of
conventional manufacturing methods for pharmaceutical products. Therefore, there has been some
research on combining these two technologies into a single continuous process in order to achieve a
more effective and efficient manufacturing process. When these two technologies are coupled into
one single process, it opens up the possibility of creating any dosage forms in-house for immediate
consumption. This is particularly useful for hospitals in remote areas. Combining these two processes
makes the fabrication of dosage forms more cost-effective, efficient and economical. Figure 9 shows a
schematic of the HME combined with FDM 3D printing into a single continuous process.
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5.1. Controlled-Release Dosage Forms
Zhang et al. have been able combine the HME and FDM 3D printing in a single process to produce
controlled-release tablets [16]. Different types of pharmaceutical polymers were made into filaments
using HME and y were loaded with Acetaminophen as a model drug. The drug relea e profiles of
the 3D printed tablets and the directly compressed tablets were being compared. The study shows that
the 3D printed tablets have better extended drug release rates than the directly compressed tablets as
they have smoother surfaces and tighter structures. The study has proven that it is possible to produce
different formulations required using a single process [16]. Zhang et al. have been able to develop
controlled-r lease 3D printed t blets by using hydroxypropyl methylc llulos (HPMC) as hy rophilic
matrix polymeric mate ial in the rug [64]. HME was used to prepa solid dispersio filam nts with
an API dispersed in HPMC based matrix. The filaments produced are fed into an FDM 3D printer to
produce controlled-release tablets with different structural design in order to obtain different drug
release profiles. Nine tablets with the same overall tablet dimensions (diameter, 10 mm; thickness,
4.5 mm) but with different outer shell thicknesses and core densities were 3D printed. The geometry
of 3D printed table s can affect the diss lution nd drug release rates. The study has pr ve that 3D
structure design is effective and efficient for optimising controlled drug release rates [64]. Goyanes et
al. have also fabricated controlled-release budesonide tablets using FDM 3D printing. The work is to
explore the feasibility of using FDM with HME and fluid bed coating to fabricate modified-release
budesonide dosage forms. Budesonide is loaded into PVA filaments using HME. An FDM 3D printer
is then used to pr duce capsule-shaped tablets (caplets) cont i ing 9 mg of budes nide. The caplets
were then overcoated with a layer of enteric polymer. The 3D printed caplet formulation started to
release drug in the mid-small intestine, but release then continued in a sustained manner throughout
the distal intestine and colon. This work has demonstrated the possibility of combining FDM 3D
printing, HME and film coating for the fabrication of modified-release oral dosage forms [65].
The work by Okwuosa et al. coordinates FDM 3D printing and liquid dispensing for the
fabrication of individualised dosage form on demand in a fully automated fashion. This work has the
potential of modifying drug dose and release. Polymethacrylate shells (Eudragit EPO and RL) were
made using FDM 3D printing and the shells were simultaneously filled using a computer-controlled
liquid dispenser loaded with a model drug solution (theophylline) or suspension (dipyridamole).
The shell thickness of 1.6mm, and concentric architecture allowed for successful containment of the
liquid core whilst maintaining the release properties of the 3D printed liquid capsule. Modifying the
shell thickness of Eudragit RL capsule allowed for a controlled extended drug release without the need
of formulation change. This type of hard shell capsule is better for taste and odour masking, improving
the patient’s compliance. This low cost and versatile approach can be adapted to a wide spectrum of
Pharmaceutics 2018, 10, 203 14 of 23
liquid formulation such as small and large molecule solutions. This method also eliminates the need
for material compatibility with the high temperature of FDM. This is the first time that an example
of a fully automated additive manufacturing process for a liquid capsule with the ability to control
the dispense dose has been demonstrated. A dual head FDM 3D printer is used here. However, one
of the printing heads has been modified to include a syringe-based liquid dispenser. The drug-free
Eudragit filaments were produced using HME. Dimethylaminoethyl methacrylate, butyl methacrylate,
and methyl methacrylate (Eudragit EPO) is used for the shell of immediate release dosage forms and
Eudragit RL is used for time controlled drug release. The dosage can be controlled by manipulating
the dispensed volume and the capsule shell thickness. This work has again proved the capability of
FDM producing individualised dosage forms [66].
5.2. Sustained-Release Dosage Forms
Chai et al. have used HME to produce hydroxypropyl cellulose (HPC) filaments that are loaded
with Domperidone (DOM) to be used in FDM 3D printers. The DOM loaded HPC filament is used to
3D print intragastric floating sustained-release tablets that have a hollow structure, which makes the
tablet have a lower density and allows it to float. The hollow structure of the tablet can be achieved
by adjusting the shell numbers and the infill percentage of the FDM 3D printing process. The study
shows that the capability of FDM 3D printers, a cost-effective platform, to produce hollow tablets
is a promising manufacturing method to fabricate intragastric floating drug delivery devices [67].
Okwuosa et al. have also used FDM 3D printers to produce delayed release shell-core gastric resistant
tablets. A dual extruder FDM 3D printer has been used to produce an enteric-coated tablet in a single
fabrication process. In this study, PVP has been used as a polymer for the core and methacrylic acid
polymer for the shell for gastric protection. Similarly, the drug loaded filament for the core and the
filament for the shell were manufactured using HME. This work has proven that the FDM 3D printer is
able to perform enteric coating to produce delayed release solid dosage forms [61]. Goyanes et al. have
been able to use FDM 3D printing to produce modified-release paracetamol tablets without the need
of an enteric coating [68]. Again, HME has been used to produce paracetamol-loaded filaments for the
use in FDM 3D printers. In this study, paracetamol is mixed with three different grades of excipients
hypromellose acetate succinate (HPMCAS) (grades LG, MG and HG) respectively. The HPMCAS-based
tablets exhibit delayed release properties, and tablets made from lower pH-threshold release drug
faster (LG has the lowest pH threshold of 5.5, MG at 6.0, and HG at 6.5). This study shows that FDM
3D printing is able to produce delayed release tablets without the need for an outer enteric coating.
The work by Li et al. has been able to combine HME and FDM to produce a novel controlled-release
drug delivery device for diabetic treatment [69]. HME was used to load Glipizide onto PVA to form
the drug-loaded filaments. A dual extruder FDM 3D printer was used to produce a double chamber
device, where a tablet is embedded within a larger tablet (DuoTablet), and both chambers contains
different doses of glipizide. The different concentration of the drug at two chambers is able to achieve
a sustained-release profile of the drug. The drug in the external layer is first released and the drug in
the second layer will only be released when the first layer has been completely dissolved, delaying
the drug release profile of the solid dosage form. This study shows the feasibility of producing a
DuoTablet with controlled-release profile in a single process [69].
Verstraete et al. conducted a study to develop high drug loaded (>30%, w/w), thermoplastic
polyurethane (TPU)-based dosage forms using FDM 3D printing. This is because TPU shown potentials
for the manufacturing of highly dosed oral sustained-release matrices via HME [70]. The drug loaded
TPU filaments were prepared using HME. Different grades of TPU were mixed with model drugs of
different particle size and solubility. Only the TPU-based filaments that exhibit consistent filament
diameter, smooth surface morphology and good mechanical properties were used in FDM printers
to be printed into tablets. It is proven that TPU-based filaments could be loaded with 60% (w/w) fine
drug powder. The hot melt extruded hard TPU filaments were successful in producing 3D printed
tablets with high concentration of crystalline drug (up to 60%, w/w). The drug release profile of the 3D
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printed tablet were dependent on the matrix composition and the tablet infill degree. The dosage and
release rate can be adjusted according to the patient’s needs by change the matrix composition and
the percentage of tablet infill. The study shows that TPU-based filaments can offer much formulation
freedom for the development of personalised dosage forms [71].
5.3. Rapid/Immediate–Release Dosage Forms
Although there is much work that has proven the ability of FDM 3D to produce various drug
delivery systems, it has not been a favoured technique when it comes to the fabrication of immediate
release tablets. This is because FDM 3D printed tablets generally have a slower dissolution rate when
compared to tablets produced using the conventional methods [72]. For instance, the FDM 3D printed
Theophylline tablets by Okwuosa et al., which is made from Eudragit® E and PVP with plasticisers
required 30 min for the drug to be completely released [62]. However, Kempin et al. explored the
possibility of improving the dissolution speed of FDM 3D printed tablets by using different types of
polymeric carriers [72]. The study carried out shows that when suitable pharmaceutical grade polymer
is being used, FDM can be used to produce immediate release tablets that contains thermolabile drugs.
The drug release profiles of pantoprazole sodium tablets made from five different polymers (PVP K12,
PEG 6000, Kollidon® VA64, PEG 20000 and poloxamer 407) were compared. The drug was loaded onto
each polymer using the HME technology to produce drug-loaded filaments. The results show that the
drug incorporated in PVP has the fastest release and can be completed within 10 min. The dissolution
rate can also be further improved by reducing the infill rate during printing to increase the porosity of
the tablet [72]. Apart from that, the study has also proven that FDM 3D can produce tablets at processing
temperatures below 100 ◦C. FDM 3D printers are known to have very high printing temperatures
(170–230 ◦C) due to the high melting temperature of the traditional polymeric filaments used and could
be inappropriate for the incorporation of thermos-sensitive drugs. However, the processing temperature
of FDM 3D printers can be lowered when suitable polymers can be made into filaments chosen as a drug
carrier. Kollamaram et al. have also been able to produce immediate release formulations (Ramipril)
through FDM 3D printing at a lower printing temperature. The drug is mixed with Kollidon VA64 and
Kollidon 12PF to achieve the immediate release effect. Drug loaded filaments were first produced using
the HME technology at 70 ◦C. The 3D printer was able to print the tablets from the filaments produced
at 90 ◦C and there was no signs of thermal drug degradation on the printed tablets. The work has
proven that FDM 3D printing can also be used to produce thermolabile and low-melting point drugs
when the drug is mixed with appropriate excipients [73]. The study by Solanki et al. have produced
FDM 3D printed tablet for rapid drug release. The model drug used is haloperidol and the drug loaded
filaments were prepared using HME. Different type of polymers were used to be made into filaments
(Kollidon® VA64, Kollicoat® IR, Affinsiol TM 15 cP and HPMCAS). Tablets of 100% and 60% infill
were printed at 210 ◦C and dissolution test were conducted at pH 2 and 6.8. For the 60% infill tablet,
complete drug release was achieved in 45 min, which was significantly faster than the 100% infill tablet.
This is because the 60% infill tablet is porous and the 100% tablet is non-poroous. The filaments made of
Kollidon® VA-64-Affinisol TM 15 cP mixtures were flexible and had optimum mechanical strength for
3D printing. The 1:1 mixture of Kollidon® VA-64 and Affinisol TM 15 cP was the most suitable polymer
system to be used for 3D printing and rapid drug release. The study has proven that FDM 3D printing
can also be used to fabricate immediate release dosage forms [74].
5.4. Drug Loaded Implants
Kempin et al. have used HME to produce quinine loaded filaments that can be used in FDM 3D
printers to produce drug loaded implants. The drug release of different type of polymers (Eudragit®
RS, Polycaprolactone (PCL), poly(L-lactide) (PLLA), and ethyl cellulose (EC)) were being compared.
The study shows that PCL has the fastest drug release whereas Eudragit and EC have the slowest drug
release. The study has proven the feasibility of FDM 3D printing to manufacture drug loaded implants
as FDM 3D printing can produce a product of almost any shape, which could be designed to function
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as an implant, and at the same time, be able to incorporate a desired drug delivery system [75]. Besides
that, Genina et al. used ethylene vinyl acetate (EVA) as a drug carrier to produce drug loaded EVA
filaments using HME. The EVA filaments were loaded with indomethacin using HME. The filaments
produced were used in FDM 3D printers to fabricate custom-made T-shaped intrauterine system (IUS)
and subcutaneous rods (SR). The aim of this work is to investigate the printability of different grades of
EVA copolymers as new feedstock material for FDM 3D printing in the fabrication of drug delivery
devices. The IUS and SR were successfully printed at a temperature just above the melting point of the
drug. The study has proven that EVA 5 polymer has the required properties to be made into filaments
for the FDM 3D printing of drug delivery systems such as IUS and SR devices [76]. Holländer et al.
have also been able to produce indomethacin loaded PCL filaments using HME. The drug loaded
PCL filaments were then used in FDM 3D printers to produce drug-containing T-shaped prototypes of
IUS. This study shows that the fabrication of controlled-release implantable devices can be achieved
using FDM 3D printing and HME technology [77]. Fu et al. have been able to use FDM 3D printing to
produce personalised progesterone-loaded vaginal rings. Progesterone was mixed with Polyethylene
Glycol (PEG) 4000 to form a solid dispersion and was cut into pieces. The mixture of PLA and PCL
(8:2), Tween 80 and the progesterone-loaded PEG were mixed in a desktop single screw extruder and
hot melt extruded in the form a filaments. The filaments were fed into FDM 3D printers to print vaginal
rings in the shape of “O”, “Y”, or “M”. The work shows that “O” ring had a higher dissolution rate
due to its higher surface area/volume ratio. The vaginal rings also have long-term sustained-release
of progesterone for more than 7 days with diffusion-controlled release behavior. It is again been
proven that HME and FDM 3D printing is an effective method to prepare personalised and customised
medications [78].
5.5. Dosage Forms with Multiple Medications
In recent years, there has also been increasing interest in developing a dosage form that contains
multiple medications [57,79,80]. Having more than one API in a dosage form can improve patient
compliance and cost-effectiveness [81]. This type of multi-active solid dosage form, also known
as polypill, is particularly useful for patients with complicated diseases, who are required to take
multiple medications in a day. The polypill can reduce the frequency of medications intake in a day
for the patient. The work by Gioumouxouzis et al. discovered the capability of FDM 3D printing to
fabricate dosage form containing two APIs. The bilayer dosage form contains two anti-diabetic drugs
(metformin and glimepride). Metformin was mixed with Eudragit® RL to achieve a sustained-release
effect and glimepride was mixed with polyvinyl alcohol (PVA) for an immediate release system. In this
study, the two APIs were incorporated into two different polymeric carriers to achieve distinct release
characteristics. The 3D printed bilayer dosage form allows for the simultaneous usage of two APIs
that are administered at different times of the day according to the patient’s needs. The drug-loaded
filaments were also manufactured using the HME technology. This study shows that FDM 3D printing
can be a promising technique for the fabrication of complex personalised medicine consisting of
different APIs that exhibit different release patterns [82]. Goyanes et al. used a dual-extruder FDM
3D printer to fabricate two different capsule-shaped oral drug delivery devices. One is a multilayer
device and the other is a two-compartment caplet (Figure 10). The multilayer device is designed in
such a way, that two adjacent layers contain different type of drugs. The two-compartment caplet
is a smaller caplet embedded in a larger caplet (Duocaplet), with each compartment containing a
different drug. In this study, PVA-based filaments were used and they were loaded with paracetamol
or caffeine. The filaments were prepared using the HME method. The drug release study shows that
for the multilayer device, drug release rates were similar for both drugs. However, if one layer has
a higher drug loading than the other, the release rate will be faster for higher drug loading. For the
Duocaplet, the drug on the external layer is being released first. The time lag of the release of drug in
the inner caplet depends on the characteristics of the external layer. The study has proven that tablets
that are 3D printed in different shapes can have different release profiles [83].
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Figure 10. A 3D computer-aided design (CAD) model of capsule-shaped oral drug delivery device
(a) multilayer device (b) two-compartment caplet (Duocaplet) (Reproduced with permission from
reference [83], American Chemical Society (ACS), 2015).
Maroni et al. used FDM 3D printing to fabricate a two-compartment capsular device for two-pulse
oral drug delivery purposes. The study carried out in this work involves the combination of two
compartments with different wall thickness and compositions. Promptly soluble, gastroresistant and
swellable/erodible compartments w re de loped, which allowed for immediate, enteric and pulsatile
release to be achieved respectively. Th refore, different types of polymeric filaments have been used to
achieve different effects. The poly eric filaments were prepared using twin-screw extrusion. Apart
from different materials, the compartments were also made to be of different wall thickness (600 µm
and 1200 µm) (Figure 11). Such a device is intended to yield multiple release kinetics. The two separate
compartments are to be filled either with different APIs or with varied doses and/or formulations of
one particular drug. These devices with different compartment characteristics show two pulse release
patterns. These two-compartment capsular devices are able to convey incompatible drugs or different
drug formulations [84].
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Tagami et al. were able to fabricate 3D-printed composite tablets consisting of two components,
a drug and a filler, using a dual head FDM 3D printer. PVA containing calcein was used as the
drug component an drug-free PVA or PLA was used as the water-soluble or water-insoluble filler
respectiv ly. The filaments were produced using a twin-screw extruder. Dif erent desi tablets
were being used. There were eight kinds of calcein-loaded PVA/PVA composite tablets and four kinds
of calcein-loa ed PVA/PLA tablets that w re 3D printed. ll composite tablets were designed to have
different surface areas of calcein-PVA but all have a drug component/filler com onent ratio of 2/3 (v/v).
The composite tablets showed various drug release profiles. The higher surface area of calcein-PVA had
a higher dissolution rate. The study shows that the polymer filler component was effective in controlling
drug release and will be particularly useful for personalised medicine [85]. The study carried out by
Melocchi et al. has successfully proven the feasibility of FDM 3D printing in the manufacturing of
capsular devices for oral pulsatile release using HPC-based filaments. Pharmaceutical grade HPC-based
filaments are not commercially available and they were produced using HME. The capsular device
produced using FDM 3D printing exhibited satisfactory physico-technological properties. The release
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test of the capsular device shows that there is a lag phase before rapid and quantitative liberation of
the drug. The morphological of the device when in contact with water and the release performance
are comparable to the analogous systems fabricated using injection moulding. Since it is possible to
rapidly prototype capsular devices using FDM 3D printing, the screening of formulation and design
characteristics of these devices are also expected to be accelerated [86].
5.6. Complex-Shaped Medicines
As FDM 3D printing can be used to produce complex personalised medicines, Arafat et al. have
been able to use 3D printers for flexible on-demand precision tailored dose adjustment [87]. This type
of medication has been beneficial for anticoagulant therapy. For anticoagulation therapy, regular
coagulation monitoring and dose modification is required in order to ensure the patient’s International
Normalised Ratio (INR) remains in the target range. Therefore, dose modification is required from time
to time, depending on the patient’s condition, as the patient’s INR profile may be constantly changing.
The 3D printing technology is able to produce a precise dose and has been a platform to fabricate
personalised medicine with the required dose. The technology allows the administration of the lowest
effective dose of the drug to maintain the target INR due to its flexible and precise manufacturing
capability. Arafat et al. have used FDM 3D printers to produce a tailored dose of a narrow therapeutic
index drug, warfarin, and have successfully fabricated this purposefully designed solid dosage form
in ovoid tablets. The study showed that FDM 3D printing can be used to engineer and control the dose
of immediate release warfarin tablets by controlling the mass and volume of the 3D printed tablet.
The drug loaded filaments were produced using a twin-screw hot-melt extruder and Triethyl citrate
(TEC) was mixed into the drug loaded filament formulation in order to lower to the glass transition
temperature of the filament [87].
Apart from that, the work done by Scoutaris et al. has also proven that a continuous process
of HME coupled with FDM 3D printing can be used to prepare chewable tablets in the shapes of
“Starmix®” sweets [54]. This is a very effective method to produce paediatric medicines as the HME
is able to provide taste masking of bitter APIs, and FDM 3D printing has the capability to produce
complex shapes tablets which could attract the attention of children. In this study, the drug used is
Indomethacin (IND) and the thermoplastic polymer used is HMPCAS. HME has efficiently dispersed
the IND in the HPMCAS matrix, providing excellent taste masking efficiency. FDM 3D printing has
shown to have high reproducibility, accuracy and content uniformity of the Starmix® shapes. This study
has proven an alternative route of producing palatable paediatric dosage forms. Jamróz et al. carried
out a study that used FDM 3D printer to prepare orodispersible films (ODFs) containing a poorly
water soluble substance, Aripiprazole. The study proves the feasibility of fabricating ODFs using FDM
technology and to improve the dissolution rate of the poorly water-soluble substance through 3D
printed films. The Aripiprazole loaded PVA filaments were prepared using HME. The study shows
that amorphisation of the aripiprazole and the porous structure of 3D printed film is able to improve
its dissolution rate. The mechanical properties of the 3D printed films were also comparable to the
films prepares using the casting method [88].
Beck et al. also carried out a study regarding an innovative approach to produce customised
drug delivery systems using FDM 3D printing. This work produced a multi-functional drug delivery
system, which is a solid dosage form loaded with nano-sized carriers. The possibility of fabricating
solid dosage form containing drug-loaded nanocapsules using FDM 3D printing has been discovered.
This work integrates the FDM 3D printing technology and nanotechnology to produce innovative
nanomedicines. PCL and Eudragit® RL100 (ERL) filaments were produced using HME. The 3D printed
tablets were then loaded with polymeric nanocapsules. The study proposed a new platform for the
development of oral dosage forms, biodegradable implants with tailored dose and drug release profiles,
as personalised medicines [89].
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6. Conclusions
HME is gradually becoming a preferred manufacturing technology in the pharmaceutical industry
due to its many advantages over conventional fabrication techniques. It has been proven to be a
very efficient technology in producing different drug delivery systems such as the solid dispersion,
modified drug release systems, and targeted drug release systems. One major advantage of the
HME is that it is more environmentally friendly as it is a solvent-free process. It is a very effective
improving the bioavailability and solubility of poorly soluble drugs, as well as taste masking the
bitterness of APIs. FDM 3D printing has also been proven to be a versatile 3D printing method. It is
a very cost-effective 3D printing method and have been used across various disciplines. FDM 3D
printing has a great potential to be the main manufacturing method for pharmaceutical devices, in
particular personalised medicines and implants, due to its flexible manufacturing capability which
allows for the fabrication of pharmaceutical products with nearly any shape. When being used
in pharmaceutics, FDM has the capability to produce complex shape dosage forms, which could
play a role in the release pattern of a drug. The advantages of using FDM in the production of
pharmaceutics include design flexibility, cost-effectiveness and high reproducibility. As FDM takes
thermoplastic filaments as printing materials, the filaments can be produced using HME. Drug loaded
filaments can be extruded from the HME and then fed directly to the FDM 3D printer. Therefore, the
HME technology and FDM can be combined into a single continuous process for higher efficiency.
The combined process provides an automatic production process and could limit material loss. When
these two technologies are coupled into one single process, it opens up the possibility of creating
any dosage forms in-house for immediate consumption. This is particularly useful for hospitals in
remote areas. This continuous process also offers the flexibility in producing formulations based on the
personal needs of patients. The personalised medicines can be produced in house for immediate use.
Combining these two processes makes the fabrication of dosage forms more cost-effective, efficient and
economical. The HME and FDM combined process has opened up the possibility of producing any
types of formulations and drug delivery systems and is a novel technique to be used in the production
of pharmaceutical dosage form and medical devices.
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